克鲁斯念珠菌中一种先前未报道的FKS1突变导致棘白菌素治疗失败病例。
Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.
作者信息
Jensen Rasmus Hare, Justesen Ulrik Stenz, Rewes Annika, Perlin David S, Arendrup Maiken Cavling
机构信息
Mycology Unit, Statens Serum Institut, Copenhagen, Denmark.
Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.
出版信息
Antimicrob Agents Chemother. 2014 Jun;58(6):3550-2. doi: 10.1128/AAC.02367-14. Epub 2014 Mar 31.
Abstract
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥ 5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
摘要
棘白菌素是治疗克鲁斯假丝酵母菌侵袭性感染的首选疗法。我们在此报告一例涉及克鲁斯假丝酵母菌的临床治疗失败病例，该菌具有一个特征性的FKS1热点突变，此前在克鲁斯假丝酵母菌中未见报道，此菌是在治疗14天后分离得到的。阿尼芬净的最低抑菌浓度（MIC）比临床断点升高了≥5个稀释梯度，但对于携带相应突变的白色假丝酵母菌分离株，MIC仅升高了1个梯度，这表明该突变导致的MIC升高存在显著的种属特异性差异。
相似文献
1
Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.
Antimicrob Agents Chemother. 2014 Jun;58(6):3550-2. doi: 10.1128/AAC.02367-14. Epub 2014 Mar 31.
2
Acquired echinocandin resistance in a Candida krusei blood isolate confirmed by mutations in the fks1 gene.
New Microbiol. 2014 Apr;37(2):237-40. Epub 2014 Apr 1.
3
Presence of L701 M mutation in the FKS1 gene of echinocandin-susceptible Candida krusei isolates.
Diagn Microbiol Infect Dis. 2018 Dec;92(4):311-314. doi: 10.1016/j.diagmicrobio.2018.07.005. Epub 2018 Jul 10.
4
Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
J Clin Microbiol. 2011 Jul;49(7):2516-21. doi: 10.1128/JCM.00201-11. Epub 2011 May 4.
5
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.
6
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Antimicrob Agents Chemother. 2008 Sep;52(9):3092-8. doi: 10.1128/AAC.00088-08. Epub 2008 Jun 30.
7
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
8
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
9
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00238-18. Print 2018 Jun.
10
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12. doi: 10.1128/AAC.00262-08. Epub 2008 Apr 28.
引用本文的文献
1
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.
Front Cell Infect Microbiol. 2021 Dec 14;11:759408. doi: 10.3389/fcimb.2021.759408. eCollection 2021.
2
Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0185621. doi: 10.1128/AAC.01856-21. Epub 2021 Dec 6.
3
Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of .
Front Microbiol. 2020 May 19;11:854. doi: 10.3389/fmicb.2020.00854. eCollection 2020.
4
Rezafungin Activity against Contemporary Nordic Clinical Isolates and Determined by the EUCAST Reference Method.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02438-19.
5
EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00659-19. Print 2019 Sep.
6
Genetic Differentiation, Diversity, and Drug Susceptibility of .
Front Microbiol. 2018 Nov 20;9:2717. doi: 10.3389/fmicb.2018.02717. eCollection 2018.
7
Population genomics shows no distinction between pathogenic Candida krusei and environmental Pichia kudriavzevii: One species, four names.
PLoS Pathog. 2018 Jul 19;14(7):e1007138. doi: 10.1371/journal.ppat.1007138. eCollection 2018 Jul.
8
Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.01926-17. Print 2018 Apr.
9
Candidemia in a major regional tertiary referral hospital - epidemiology, practice patterns and outcomes.
Antimicrob Resist Infect Control. 2017 Mar 11;6:27. doi: 10.1186/s13756-017-0184-1. eCollection 2017.
10
Echinocandin Resistance in Candida Species: a Review of Recent Developments.
Curr Infect Dis Rep. 2016 Dec;18(12):42. doi: 10.1007/s11908-016-0549-2.
本文引用的文献
1
EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.
Mycoses. 2014 Jun;57(6):377-9. doi: 10.1111/myc.12170. Epub 2014 Jan 13.
2
Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Antimicrob Agents Chemother. 2014;58(4):1897-906. doi: 10.1128/AAC.02163-13. Epub 2014 Jan 6.
3
Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:54-9. doi: 10.1111/1469-0691.12495. Epub 2014 Jan 28.
4
Candida and candidaemia. Susceptibility and epidemiology.
Dan Med J. 2013 Nov;60(11):B4698.
5
Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.
Antimicrob Agents Chemother. 2013 Sep;57(9):4559-61. doi: 10.1128/AAC.01144-13. Epub 2013 Jul 1.
6
Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.
Clin Microbiol Infect. 2013 Aug;19(8):E343-53. doi: 10.1111/1469-0691.12212. Epub 2013 Apr 22.
7
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
8
Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.
Antimicrob Agents Chemother. 2013 May;57(5):2380-2. doi: 10.1128/AAC.02037-12. Epub 2013 Feb 25.
9
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.
Antimicrob Agents Chemother. 2013 Jan;57(1):614-7. doi: 10.1128/AAC.01193-12. Epub 2012 Oct 22.
10
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
Zotero 插件